

Special Issue

Adjuvant Therapy for Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is one of the deadliest cancers with a dismal prognosis. The currently employed radiological tests are ineffective for identifying micro-metastatic disease, which indicates the requirement of biomarkers for the early detection of metastatic features in PDAC patients. Furthermore, the effect of adjuvant radiation therapy leading to improved outcomes of PDAC patients is debatable, owing to the scarcity of data that can validate the techniques and dosage used for radiotherapy. This Special Issue will highlight the current treatment options in pancreatic cancer, the progress demonstrated by new strategies, future prospects for improving targeted therapies and effective neoadjuvant therapies that offer improved survival benefits to patients with this extremely complex and heterogeneous disease.

Guest Editor

Dr. Sonam Kumari

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/170037

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)